We are pleased to announce our newest publication in the Cardiovascular Revascularization Medicine from the desk of Prof. Nicolas van Mieghem and Dr. Marcelo Bastos. MCS is increasingly used in the context of high-risk percutaneous coronary intervention (PCI). The effect of the pulsatile iVAC 2L MCS on left ventricular loading conditions and myocardial oxygen consumption (MVO2) is unknown. In this publication, the Erasmus University Medical Centre & Kings College London showcase their clinical experiences with the iVAC 2L device and outline the impact on patients with advanced coronary artery disease at high to prohibitive operative risk in their practice. Please check this link for the full publication.
In this video series, Professor Nicolas van Mieghem will discuss the benefits of iVAC 2L in clinical practice and will share the learnings and key outcomes from the PULSE-Trial, and the effect of next generation pulsatile mechanical circulatory support (MCS). Also this video series has been broken down into 12 shorter clips. ivermectin drops for birds Please follow this link.
An expert consensus has been released by the Joint European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Association for Acute Cardiovascular Care (ACVC) reviewing the pathophysiological context and indications for pVADs in different clinical settings. It also provides guidance regarding the clinical management of patients requiring pVADs. A quick overview is made on the state-of-the art of short-term mechanical circulatory support according to different indications. Additional discussions on the handling of complications, anticoagulation and weaning are also provided. The appendix section describes the theoretical basis for the use of different MCS devices, including how their effects differ. The review has been published on EuroIntervention. Please follow this link for the full publication.
Dr. Ota Hlinomaz, interventional cardiologist at CINRE hospital in Slovak Republic presented during the EuroPCR 2021: Improving outcomes of high-risk protected distal left main intervention by pulsatile circulatory support system. For more information please follow this link.
B.G. Alekyan, N.G. Karapetyan, A.Ya. Novak , G.P. Plotnikov, Yu.B. Knysh, G.S. Grigoryan A.V. Vishnevsky National Medical Research Center of Surgery, Moscow Please follow this link: Casereport Moscow September 2020 for the full casereport
Carsten Tschöpe, Alessio Alogna, Alessandro Faragli, Karin Klingel, Gunther Schmidt, Torsten Wolfgang Heilmann, Marcelo B. ivermectin dosage for foals Bastos and Frank Spillmann Please follow this link: Casereport Berlin September 2020 for the full casereport
Please follow this link to the publication.
Prof.Dr. Nicolas van Mieghem, Erasmus Medical Center Brief Summary: The objective of this study is to determine ventricular loading conditions during and after PulseCath® iVAC 2L support, and assess its impact on specific load dependent humoral factors and cardiac enzymes. These specific patterns are so far unknown and will be compared with the validated FDA-cleared and CE marked Impella CP. Three cases with Impella CP will be performed in this study to obtain the exact same measurements for comparing purposes. لعبة go For more information about this trial, please follow this link.
Marcelo B Bastos , Maarten P van Wiechen & Nicolas M Van Mieghem*, Department of Interventional Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands *Author for correspondence: Tel.: +31 010 703 5260; Fax: +31 010 436 9154; email@example.com Please follow this link for the publication.
B. Bastos M. 1 , JJ. Schreuder 1 , J. Daemen 1 , CA. Den Uil 1,2 , NM. Van Mieghem 1 (1) Erasmus Medical Center, Interventional Cardiology, Rotterdam, Netherlands (2) Erasmus Medical Center, Department of Intensive Care Medicine, Rotterdam, Netherlands Click here to read the Poster ACURE 20.08.219